NCT04980482

Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection

A Randomized, Open-Label, Multicenter Study Investigating AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a Treatment in Subjects With Chronic Hepatitis B Infection

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 43 (actual)
• Sponsor: Arbutus Biopharma Corporation · Industry
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

This is a randomized, open label, multicenter Phase 2 study investigating the safety and antiviral activity of AB-729 in combination with ongoing NA therapy and short courses of Peg-IFNα-2a in subjects with CHB.

Conditions

• Chronic Hepatitis b

Interventions

Type	Name	Description
DRUG	AB-729	subcutaneous injection
DRUG	Peg-IFNα-2a	subcutaneous injection

Timeline

• Start date: 2021-10-29
• Primary completion: 2025-03-13
• Completion: 2025-05-21
• First posted: 2021-07-28
• Last updated: 2025-10-22

Locations

17 sites across 7 countries: United States, Australia, Hong Kong, Moldova, South Korea, Taiwan, Ukraine

Regulatory

• FDA-regulated drug study